Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes

Robert F Storey*, Paul A Gurbel, Jurrien Ten Berg, Corine Bernaud, George D Dangas, Jean-Marie Frenoux, Diana A Gorog, Abdel Hmissi, Vijay Kunadian, Stefan K James, Jean-Francois Tanguay, Henry Tran, Dietmar Trenk, Mike Ufer, Pim Van der Harst, Arnoud W J Van't Hof, Dominick J Angiolillo

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article numberehz807
Pages (from-to)3132-3140
Number of pages9
JournalEuropean Heart Journal
Volume41
Issue number33
Early online date14 Nov 2019
DOIs
Publication statusPublished - 1 Sep 2020

Keywords

  • Selatogrel
  • Platelet aggregation
  • Coronary artery disease
  • P2Y(12) receptor antagonist
  • Pharmacodynamics
  • Pharmacokinetics
  • ELEVATION MYOCARDIAL-INFARCTION
  • ANTIPLATELET THERAPY
  • TICAGRELOR
  • PRASUGREL
  • CLOPIDOGREL
  • INHIBITION
  • DYSPNEA
  • INTERVENTION
  • ACT-246475
  • MORPHINE

Cite this